Vanguard Fiduciary Trust
ZNTL icon

Vanguard Fiduciary Trust’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63M Buy
336,940
+32,469
+11% +$130K ﹤0.01% 2786
2026
Q1 		$712K Buy
+304,471
New +$786K ﹤0.01% 3076

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Fiduciary Trust's ZNTL Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Zentalis Pharmaceuticals (ZNTL) stake by 11% in Q2 2026, buying an estimated $130K and bringing the position to 336,940 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2786.

Vanguard Fiduciary Trust first reported a position in ZNTL in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Vanguard Fiduciary Trust held 336,940 shares of Zentalis Pharmaceuticals worth $1.63M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 32,469 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $130K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2786 holding.
  • Vanguard Fiduciary Trust first reported a position in Zentalis Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.